Alberto Gabizon
15Patents
7h-index
10Co-inventors
63Inventor score
Filing activity: Dec 6, 1985 → Jan 11, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US4920016A | Liposomes with enhanced circulation time | Emerging Cross-Sectional Technologies | 288 | Expired |
| US4797285A | Lipsome/anthraquinone drug composition and method | Emerging Cross-Sectional Technologies | 102 | Expired |
| US6787132B1 | Combined chemo-immunotherapy with liposomal drugs and cytokines | Human Necessities | 69 | Expired |
| US6365179B1 | Conjugate having a cleavable linkage for use in a liposome | Emerging Cross-Sectional Technologies | 40 | Expired |
| US4898735A | Liposome/doxorubicin composition and method | Emerging Cross-Sectional Technologies | 29 | Expired |
| US5043166A | Liposome/anthraquinone drug composition and method | Human Necessities | 26 | Expired |
| US6984396B2 | Conjugate having a cleavable linkage for use in a liposome | Emerging Cross-Sectional Technologies | 8 | Expired |
| US7276248B2 | Conjugate having a cleavable linkage for use in a liposome | Emerging Cross-Sectional Technologies | 4 | Expired |
| US7303760B2 | Method for treating multi-drug resistant tumors | Human Necessities | 3 | Expired |
| US10080807B2 | Combination chemotherapy comprising a liposomal prodrug of mitomycin C | Human Necessities | 1 | Active |
| US9937261B2 | Combination therapy comprising a liposomal prodrug of mitomycin C and radiotherapy | Human Necessities | 1 | Active |
| US10617672B2 | Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C | Human Necessities | 1 | Active |
| US10085940B2 | Liposomes co-encapsulating a bisphosphonate and an amphipathic agent | Human Necessities | 0 | Active |
| US12171746B2 | Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture | Human Necessities | 0 | Active |
| US8932627B2 | Liposomal compositions of glucocorticoid and glucocorticoid derivatives | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.